CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-19 | MANCHESTER KEITH S Director | Sale | −175,000 | $20.24 | $3.5M | 18,047,727 |
| 2025-11-19 | Gold Daniel Allen Director | Sale | −850,000 | $20.25 | $17.2M | 18,497,727 |
| 2025-11-19 | Gold Daniel Allen Director | Sale | −150,000 | $20.20 | $3.0M | 18,347,727 |
| 2025-11-19 | Gold Daniel Allen Director | Sale | −125,000 | $20.16 | $2.5M | 18,222,727 |
| 2025-11-19 | Gold Daniel Allen Director | Sale | −175,000 | $20.24 | $3.5M | 18,047,727 |
| 2025-11-19 | QVT Financial LP Director by Deputization | Sale | −850,000 | $20.25 | $17.2M | 18,497,727 |
| 2025-11-19 | QVT Financial LP Director by Deputization | Sale | −150,000 | $20.20 | $3.0M | 18,347,727 |
| 2025-11-19 | QVT Financial LP Director by Deputization | Sale | −125,000 | $20.16 | $2.5M | 18,222,727 |
| 2025-11-19 | QVT Financial LP Director by Deputization | Sale | −175,000 | $20.24 | $3.5M | 18,047,727 |
| 2025-11-17 | Ramaswamy Vivek 10% owner | Sale | −539,650 | $20.51 | $11.1M | 33,653,756 |
| 2025-11-14 | Ramaswamy Vivek 10% owner | Sale | −1,027,670 | $20.33 | $20.9M | 34,193,406 |
| 2025-11-13 | Ramaswamy Vivek 10% owner | Sale | −287,283 | $20.81 | $6.0M | 35,221,076 |
| 2025-11-07 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +200,000 | $3.85 | $770K | 1,704,959 |
| 2025-11-07 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $20.22 | $4.0M | 1,504,959 |
| 2025-11-07 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200,000 | $20.22 | $4.0M | 6,076,523 |
| 2025-10-20 | Epperly Melissa B, Director | Grant or award | +1,056 | 56,904 | ||
| 2025-10-20 | MOMTAZEE JAMES C Director | Grant or award | +789 | 108,701 | ||
| 2025-10-20 | MOMTAZEE JAMES C Director | Shares withheld for taxes | −158 | $17.74 | $3K | 108,543 |
| 2025-10-20 | Oren Ilan Director | Grant or award | +1,507 | 118,669 | ||
| 2025-10-20 | Oren Ilan Director | Shares withheld for taxes | −281 | $17.74 | $5K | 118,388 |
Page 16 of 29 · 570 trades